BACKGROUND: Parkinson's disease (PD) is a complex multi-system age-related neurodegenerative disorder. Targeting the ongoing neuroinflammation in PD patients is one strategy postulated to slow down or halt disease progression. Proof-of-concept studies from our group demonstrated that selective inhibition of soluble Tumor Necrosis Factor (solTNF) by intranigral delivery of dominant negative TNF (DN-TNF) inhibitors reduced neuroinflammation and nigral dopamine (DA) neuron loss in endotoxin and neurotoxin rat models of nigral degeneration. OBJECTIVE: As a next step toward human clinical trials, we aimed to determine the extent to which peripherally administered DN-TNF inhibitor XPro®1595 could: i) cross the blood-brain-barrier in therapeutically relevant concentrations, ii) attenuate neuroinflammation (microglia and astrocyte), and iii) mitigate loss of nigral DA neurons in rats receiving a unilateral 6-hydroxydopamine (6-OHDA) striatal lesion. METHODS: Rats received unilateral 6-OHDA (20 μg into the right striatum). Three or 14 days after lesion, rats were dosed with XPro®1595 (10 mg/kg in saline, subcutaneous) every third day for 35 days. Forelimb asymmetry was used to assess motor deficits after the lesion; brains were harvested 35 days after the lesion for analysis of XPro®1595 levels, glial activation and nigral DA neuron number. RESULTS: Peripheral subcutaneous dosing of XPro®1595 achieved plasma levels of 1-8 microgram/mL and CSF levels of 1-6 ng/mL depending on the time the rats were killed after final XPro®1595 injection. Irrespective of start date, XPro®1595 significantly reduced microglia and astrocyte number in SNpc whereas loss of nigral DA neurons was attenuated when drug was started 3, but not 14 days after the 6-OHDA lesion. CONCLUSIONS: Our data suggest that systemically administered XPro®1595 may have disease-modifying potential in PD patients where inflammation is part of their pathology.
BACKGROUND:Parkinson's disease (PD) is a complex multi-system age-related neurodegenerative disorder. Targeting the ongoing neuroinflammation in PDpatients is one strategy postulated to slow down or halt disease progression. Proof-of-concept studies from our group demonstrated that selective inhibition of soluble Tumor Necrosis Factor (solTNF) by intranigral delivery of dominant negative TNF (DN-TNF) inhibitors reduced neuroinflammation and nigral dopamine (DA) neuron loss in endotoxin and neurotoxin rat models of nigral degeneration. OBJECTIVE: As a next step toward human clinical trials, we aimed to determine the extent to which peripherally administered DN-TNF inhibitor XPro®1595 could: i) cross the blood-brain-barrier in therapeutically relevant concentrations, ii) attenuate neuroinflammation (microglia and astrocyte), and iii) mitigate loss of nigral DA neurons in rats receiving a unilateral 6-hydroxydopamine (6-OHDA) striatal lesion. METHODS:Rats received unilateral 6-OHDA (20 μg into the right striatum). Three or 14 days after lesion, rats were dosed with XPro®1595 (10 mg/kg in saline, subcutaneous) every third day for 35 days. Forelimb asymmetry was used to assess motor deficits after the lesion; brains were harvested 35 days after the lesion for analysis of XPro®1595 levels, glial activation and nigral DA neuron number. RESULTS: Peripheral subcutaneous dosing of XPro®1595 achieved plasma levels of 1-8 microgram/mL and CSF levels of 1-6 ng/mL depending on the time the rats were killed after final XPro®1595 injection. Irrespective of start date, XPro®1595 significantly reduced microglia and astrocyte number in SNpc whereas loss of nigral DA neurons was attenuated when drug was started 3, but not 14 days after the 6-OHDA lesion. CONCLUSIONS: Our data suggest that systemically administered XPro®1595 may have disease-modifying potential in PDpatients where inflammation is part of their pathology.
Authors: Melissa K McCoy; Terina N Martinez; Kelly A Ruhn; David E Szymkowski; Christine G Smith; Barry R Botterman; Keith E Tansey; Malú G Tansey Journal: J Neurosci Date: 2006-09-13 Impact factor: 6.167
Authors: Honglei Chen; Eric Jacobs; Michael A Schwarzschild; Marjorie L McCullough; Eugenia E Calle; Michael J Thun; Alberto Ascherio Journal: Ann Neurol Date: 2005-12 Impact factor: 10.422
Authors: Paul M Steed; Malú G Tansey; Jonathan Zalevsky; Eugene A Zhukovsky; John R Desjarlais; David E Szymkowski; Christina Abbott; David Carmichael; Cheryl Chan; Lisa Cherry; Peter Cheung; Arthur J Chirino; Hyo H Chung; Stephen K Doberstein; Araz Eivazi; Anton V Filikov; Sarah X Gao; René S Hubert; Marian Hwang; Linus Hyun; Sandhya Kashi; Alice Kim; Esther Kim; James Kung; Sabrina P Martinez; Umesh S Muchhal; Duc-Hanh T Nguyen; Christopher O'Brien; Donald O'Keefe; Karen Singer; Omid Vafa; Jost Vielmetter; Sean C Yoder; Bassil I Dahiyat Journal: Science Date: 2003-09-26 Impact factor: 47.728
Authors: Honglei Chen; Shumin M Zhang; Miguel A Hernán; Michael A Schwarzschild; Walter C Willett; Graham A Colditz; Frank E Speizer; Alberto Ascherio Journal: Arch Neurol Date: 2003-08
Authors: S Przedborski; M Levivier; H Jiang; M Ferreira; V Jackson-Lewis; D Donaldson; D M Togasaki Journal: Neuroscience Date: 1995-08 Impact factor: 3.590
Authors: Alexander Gerhard; Nicola Pavese; Gary Hotton; Federico Turkheimer; Meltem Es; Alexander Hammers; Karla Eggert; Wolfgang Oertel; Richard B Banati; David J Brooks Journal: Neurobiol Dis Date: 2005-09-21 Impact factor: 5.996
Authors: Valerie Joers; Gunasingh Masilamoni; Doty Kempf; Alison R Weiss; Travis M Rotterman; Benjamin Murray; Gul Yalcin-Cakmakli; Ronald J Voll; Mark M Goodman; Leonard Howell; Jocelyne Bachevalier; Stefan J Green; Ankur Naqib; Maliha Shaikh; Phillip A Engen; Ali Keshavarzian; Christopher J Barnum; Jonathon A Nye; Yoland Smith; Malú G Tansey Journal: Neurobiol Dis Date: 2020-07-24 Impact factor: 5.996
Authors: Maria Karamita; Christopher Barnum; Wiebke Möbius; Malú G Tansey; David E Szymkowski; Hans Lassmann; Lesley Probert Journal: JCI Insight Date: 2017-04-20
Authors: Samuel J Rose; Porter Harrast; Christine Donsante; Xueliang Fan; Valerie Joers; Malú G Tansey; H A Jinnah; Ellen J Hess Journal: Mov Disord Date: 2017-09-26 Impact factor: 10.338
Authors: Prabarna Ganguly; Jennifer A Honeycutt; June R Rowe; Camila Demaestri; Heather C Brenhouse Journal: Brain Behav Immun Date: 2019-01-14 Impact factor: 7.217
Authors: Shetty Ravi Dyavar; Lisa F Potts; Goichi Beck; Bhagya Laxmi Dyavar Shetty; Benton Lawson; Anthony T Podany; Courtney V Fletcher; Rama Rao Amara; Stella M Papa Journal: Genes Brain Behav Date: 2020-09-11 Impact factor: 3.449
Authors: Inga Peter; Marla Dubinsky; Susan Bressman; Andrew Park; Changyue Lu; Naijun Chen; Anthony Wang Journal: JAMA Neurol Date: 2018-08-01 Impact factor: 18.302
Authors: Anwesha Sanyal; Mark P DeAndrade; Hailey S Novis; Steven Lin; Jianjun Chang; Nathalie Lengacher; Julianna J Tomlinson; Malú G Tansey; Matthew J LaVoie Journal: Mov Disord Date: 2020-02-08 Impact factor: 10.338
Authors: Kathryn P MacPherson; Pradoldej Sompol; George T Kannarkat; Jianjun Chang; Lindsey Sniffen; Mary E Wildner; Christopher M Norris; Malú G Tansey Journal: Neurobiol Dis Date: 2017-02-24 Impact factor: 5.996